Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glycotex has obtained an active investigational new drug application from the FDA for the start of a randomized, double-blind, placebo-controlled Phase IIa clinical trial of its lead topical product candidate GLYC-101, for the treatment of burn wounds.
Subscribe to our email newsletter
The Phase IIa human clinical trial to be conducted in the US is designed to investigate the safety and clinical outcomes of topically applied GLYC-101 compared to placebo in subjects undergoing carbon dioxide laser skin resurfacing.
GLYC-101 has already completed a Phase II human clinical trial in Australia for the treatment of chronic venous skin ulcers. Glycotex intends to develop GLYC-101 for a wide range of human wound healing and tissue repair applications including burn wounds, post surgical wounds, diabetic ulcers and chronic venous ulcers.